Blog

Managing Behavioural Changes During Treatment for Leukemia

 


VIEW THE PRESENTATION

Speaker:
Nina Kadan-Lottick, MD, MSPH
Associate Professor of Pediatrics
Director of HEROS Survivorship Program
Leader Clinical Trial Program
Section of Pediatric Hematology-Oncology
Yale University School of Medicine, New Haven, CT

Dr. Kadan-Lottick, a pediatric hematologist-oncologist, is an Associate Professor at the Yale University School of Medicine and Director of the Yale HEROS Program for childhood cancer survivors. Dr. Kadan-Lottick’s research has concentrated on measuring and optimizing outcomes after treatment of childhood cancer, with an emphasis on leukemia. These studies have included cross-sectional and longitudinal studies of chemotherapy-induced cognitive changes, anxiety and depression, and family functioning during and after therapy. She was the principal investigator of two large multi-site longitudinal studies of quality of life outcomes and emotional functioning in children with acute lymphoblastic leukemia enrolled on front-line Children’s Oncology Group (COG) clinical trials. As a part of her focus on survivorship outcomes, Dr. Kadan-Lottick serves on the Children’s Oncology Group Survivorship Steering Committee, the Psychology Committee of the Childhood Cancer Survivorship Cohort Study, Consortium for New England Childhood Cancer Survivors Steering Committee, and the Board of Trustees for the Connecticut Chapter of the Leukemia and Lymphoma Society. She has also helped to author and revise the COG Long-Term Follow-up Guidelines.

Comments are closed.